Author

Feng-Min Zhao

h-index 5 View on Semantic Scholar

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Pathologic complete response (pCR) rate and factors associated with pCR after taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181

Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER− and one-third with HER2+/ER+ breast cancer, and these findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.

N. Tung, Feng-Min Zhao, A. DeMichele et al. · Journal of Clinical Oncology · 2 citations

Open access Aug 2026

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Ulixertinib had no demonstrable evidence of clinical activity in this small, heavily pretreated population of patients with tumors harboring BRAF fusions, or with non-V600E, non-V600K BRAF mutations.

V. Subbiah, Feng-Min Zhao, R. Kudchadkar et al. · Clinical Cancer Research · 0 citations